NJ News (4/22, Dearing) reports on epigenetics research efforts going on in New Jersey to help develop new medications for the treatment of Alzheimer’s. For example, “Princeton Medical Institute is the first study site in the United States to join a clinical trial for ORY-2001, a drug designed to slow cognitive decline and restore memory in patients with mild to moderate Alzheimer’s disease.” Should the experimental medicine be effective, “patients taking part in the study will have already received the drug rather than having to wait years for it to gain FDA approval and become available to the public. (SOURCE: APA Headlines)
- ) strategy and implementation of activities aimed at increased supports for caregivers of persons with mental illness, in addition to the continued work of the Coalition and sustaining the collaboration between aging and behavioral health providers at the local level.
- Studies Support Effectiveness Of Ketamine, Esketamine For Difficult-To-Treat Depression, MDD With Suicidal Ideation, Expert Says
- In Small Study, Investigational Nondopamine Antipsychotic Show Signals It May Improve Psychosis Symptoms In Patients With Parkinson’s Disease
- Benzoate Treatment Appears To Improve Cognitive Function Among Women With Later-Stage Dementia In Small Study
- More Than One In Ten Patients Who Receive An ICD May Also Develop Anxiety Or Depression, Research Suggests